Buffington Mohr McNeal Buys 5,200 Shares of Pfizer Inc. (NYSE:PFE)

Buffington Mohr McNeal boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 41.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,650 shares of the biopharmaceutical company’s stock after purchasing an additional 5,200 shares during the period. Buffington Mohr McNeal’s holdings in Pfizer were worth $508,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC increased its holdings in Pfizer by 89,592.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after buying an additional 160,963,976 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Pfizer by 10.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after buying an additional 9,393,992 shares during the last quarter. Morgan Stanley increased its holdings in Pfizer by 0.4% during the third quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock valued at $2,817,055,000 after buying an additional 348,628 shares during the last quarter. Norges Bank purchased a new stake in Pfizer during the fourth quarter valued at approximately $3,150,472,000. Finally, Massachusetts Financial Services Co. MA increased its holdings in Pfizer by 9.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock valued at $1,997,083,000 after buying an additional 5,185,453 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on PFE. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Stock Down 0.4 %

Shares of PFE stock traded down $0.11 during trading hours on Tuesday, reaching $25.80. 13,327,945 shares of the stock were exchanged, compared to its average volume of 42,333,582. The business’s fifty day moving average is $27.27 and its two-hundred day moving average is $28.84. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a 12-month low of $25.61 and a 12-month high of $41.33. The firm has a market capitalization of $146.09 billion, a P/E ratio of 71.69, a P/E/G ratio of 1.16 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm’s revenue was down 41.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.14 earnings per share. As a group, research analysts expect that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.